MUNICH--Genome Pharmaceuticals, a functional genomics company here, has announced a new six-member board of directors. Members include Juergen Drews, president of global research for Hoffmann-La Roche; Ansbert Gaedicke, managing director of Venture Asset Management; Hans Lehrach, director and scientific cofounder of the Max Planck Institute for Molecular Genetics; Helmut Schuehsler, managing partner of TVM Techno Venture Management; Wolfgang Stoiber, managing director of MPM Capital; Ernst-Ludwig Winnacker, director of the Gene Center Munich and president of the Deutsche Forschungsgemeinschaft.
The appointments coincided with a corporate reorganization which, according to Elmar Maier, vice-president of business development, "will provide us with new advantages in Germany, such as equity-based compensation and financing strategies. This will help us attract outstanding individuals to the company and rapidly expand our business." Genome Pharmaceuticals offers an integrated platform of automated high-throughput genomic technologies that includes gene expression analyses, protein interaction mapping, and bioinformatics tools. It plans to collaborate with pharmaceutical companies, offering a combination of three genomic databases.